Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis.
Publication/Presentation Date
5-13-2025
Abstract
BACKGROUND AND AIMS: Tyrosine kinase 2 is a downstream intracellular mediator of interleukin-23 signaling, which has a key role in the pathogenesis of inflammatory bowel disease. Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 inhibitor currently approved for the treatment of adults with moderate to severe plaque psoriasis.
METHODS: Here we describe three randomized, double-blind, placebo-controlled phase 2 studies of deucravacitinib in patients with moderately to severely active Crohn's disease (LATTICE-CD [NCT03599622]) or ulcerative colitis (LATTICE-UC [NCT03934216] and IM011-127 [NCT04613518]). Patients were randomized to receive placebo or twice-daily deucravacitinib 3 mg or 6 mg (LATTICE-CD), 6 mg (LATTICE-UC), or 12 mg (IM011-127) for 12 weeks. Coprimary endpoints for LATTICE-CD were clinical remission and endoscopic response at Week 12. The primary endpoint was clinical remission (per modified Mayo score) at Week 12 for LATTICE-UC and clinical response (per modified Mayo score) at Week 12 for IM011-127.
RESULTS: A total of 239 (LATTICE-CD), 131 (LATTICE-UC), and 38 (IM011-127) patients were randomized. The primary endpoints were not met for all three studies, which resulted in early study termination for LATTICE-CD and IM011-127. High efficacy rates were observed in placebo groups throughout the studies. In all studies, the safety profile of deucravacitinib was consistent with the known safety profile observed in patients with psoriasis, and no new safety signals were observed.
CONCLUSIONS: Deucravacitinib at multiple doses did not demonstrate significant clinical benefit vs placebo in moderately to severely active Crohn's disease or ulcerative colitis. Deucravacitinib was safe and well-tolerated.
ISSN
1876-4479
Published In/Presented At
D'Haens, G., Danese, S., Panaccione, R., Rubin, D. T., Peyrin-Biroulet, L., Matsuoka, K., Loftus, E. V., Jr, Kobayashi, T., Elsharkawi, W., Miceli, R., Ahmed, S., Luo, Y., Napoli, A., Vaile, J., Dornic, Q., Patel, A., & Schreiber, S. (2025). Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis. Journal of Crohn's & colitis, jjaf080. Advance online publication. https://doi.org/10.1093/ecco-jcc/jjaf080
Disciplines
Medicine and Health Sciences
PubMedID
40355364
Department(s)
Fellows and Residents
Document Type
Article